Moderna and Merck’s Personalized mRNA Vaccine Shows Promise in Melanoma Trial

A Phase 3 study of the personalized mRNA vaccine intismeran autogene with Merck’s Keytruda met its primary endpoint of recurrence-free survival in patients whose surgically removed melanomas carried a high risk of returning. The trial, enrolling over 1,000 participants, also achieved distant-metastasis-free survival. Investigators reported no new safety signals; the side-effect profile was comparable to Keytruda alone.

CNN

Intismeran autogene uses messenger-RNA technology first deployed in COVID-19 vaccines. Each dose is custom-manufactured from the mutations identified in an individual’s tumor, targeting up to 34 neoantigens. Earlier mid-stage data showed roughly a 50 % reduction in recurrence and a 59 % cut in metastatic spread when added to Keytruda. This is the first successful late-stage trial of an individualized neoantigen therapy.

Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

• Enrollment: > 1,000 high-risk melanoma patients (stages IIB-IV) with fully resected tumors.

Scientific American

• Efficacy: Recurrence-free survival was significantly longer for the combination arm; prior five-year data indicated ? 50 % lower risk of recurrence and ? 59 % lower risk of distant metastasis versus Keytruda alone.

Scientific American

• Safety: No increase in serious adverse events; reactions mirrored typical vaccine responses such as mild flu-like symptoms.

Gizmodo

• Manufacturing: Six to eight weeks from tumor sequencing to final product.

Newsweek

A Moderna spokesperson said the full dataset will be presented at an upcoming international medical meeting, while Merck called the trial a “landmark moment” for adjuvant melanoma therapy. Both companies emphasized ongoing monitoring of overall survival, which remains unreported.

Newsday

• Dr. Robert Vonderheide, Penn Medicine expressed optimism that forthcoming studies will yield positive outcomes.

CNN

• Stephen Hoge, Moderna president compared vaccine reactions to those seen after flu or COVID-19 shots.

CNN

• Cathy Bradley, Colorado School of Public Health highlighted the potential for such vaccines to offset costly downstream treatments.

Newsweek

If approved, intismeran could establish a new paradigm in which post-surgical cancer patients receive a bespoke immunotherapy designed to eradicate residual disease. The technology may extend beyond melanoma to lung, bladder, kidney and other solid tumors under investigation. By preventing recurrence, personalized vaccines could reduce long-term treatment costs and shift certain cancers toward chronic-disease management.

NewsweekModerna and Merck cancer vaccine success paves way for future GizmodoCNNFrench oncologist calls personalized skin cancer vaccine ‘real hope’ after Moderna, Merck trial results

The companies have not released complete numerical results, and peer-reviewed publication is pending. Consequently, the precise magnitude of recurrence-risk reduction and overall-survival benefit remains unverified. Regulatory timelines are projected but not fixed, and reimbursement frameworks for individualized therapies have yet to be defined.

Newsweek

Regulators are expected to receive formal submissions within the next two years, with detailed Phase 3 data slated for presentation at an international oncology conference later this year. Ongoing trials are evaluating the same mRNA platform in non-small-cell lung cancer, bladder cancer, kidney cancer and early-stage pancreatic and stomach cancers.

CNN